Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chikungunya virus vaccine - Themis Bioscience

Drug Profile

Chikungunya virus vaccine - Themis Bioscience

Alternative Names: Measles-vectored Chikungunya vaccine; MV-CHIK; MV-CHIK/DP

Latest Information Update: 14 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Themis Bioscience
  • Developer National Institute of Allergy and Infectious Diseases; Themis Bioscience
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chikungunya virus infections

Most Recent Events

  • 10 Oct 2019 Themis Bioscience completes a phase-II clinical trials in Chikungunya virus infections (Prevention) in United Kingdom (IM) (NCT03635086) (EudraCT2018-000211-25)
  • 16 Jul 2019 Themis Bioscience initiates enrolment in a phase II trial for Chikungunya virus infection (Prevention) in Puerto Rico (IM) (NCT03807843)
  • 04 Jun 2019 Themis Bioscience announces intention to submit clinical trial application to regulatory authorities for Chikungunya virus infections in second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top